Lonza
Manufacturing · Switzerland · 18,000 Employees
View Company Info for Free
About
Headquarters
38 Muenchensteinerstrasse, Basel, Basel-City, 4...Phone Number
+41 613168111Website
lonza.comRevenue
$7.9 BillionStock Symbol
LZAGFIndustry
Most Recent Scoops
Who is Lonza
Lonza Org Chart
Is Lonza your ideal customer?
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Lonza
Product Launch: Get notified when Lonza launches new products
Lonza, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Lonza has new funding data
Website visits: Recent activity has been detected on your website
Check if Lonza has recently received funding, and reach out quickly before it becomes old news!
Click to see if Lonza had a recent Job posting/layoffs
Check out if Lonza is spiking on competitors!
Earning: See what the market has to say on Lonza recently announced quarterly report
Recommended Actions
Find VP level buyers at Lonza
Find 3 more new buyers
Compare Similar Companies to Lonza
Compare insights from companies similar to Lonza, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Lonza Email Formats
Lonza uses at least 5 email formats with first.last (ex. John.Smith@lonza.com) being used 81.8% of the time
Lonza Email Formats | Percentage | |
---|---|---|
first.last | John.Smith@lonza.com | 81.8% |
first + last | JohnSmith@lonza.com | |
first_last | John_Smith@lonza.com | |
first | John@lonza.com | |
last | Smith@lonza.com |
Get Verified Emails
Lonza Employee Growth Rate
Percentage of growth
1st year Mask
2nd year Mask
Lonza Tech Stack
A closer look at the technologies used by Lonza
Most Recent Scoops
Lonza News & Media
Lonza's Synaffix Collaborates with BigHat Biosciences on the Development of a Machine Learning-Designed ADC
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies Collaboration underscores Lonza's commitment to helping customers deliver innovative new therapies to patients by offering a comprehensive service offering for...Lonza completes acquisition of large-scale biologics site from Roche
Lonza announced it has completed its acquisition of the Genentech large-scale biologics manufacturing site in Vacaville, California (US) from Roche for USD 1.2 billion.Lonza Completes Acquisition of Vacaville, CA Site from Roche
The acquisition of the Vacaville facility significantly extends Lonza’s capacity for mammalian manufacturing in the U.S.Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease
NEWTON, Mass., and BASEL, Switzerland, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta (Aβ) oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), announced today that it has extended its collaboration with Lonza to enable the potential future commercial launch of sabirnetug (ACU193).
Frequently Asked Questions Regarding Lonza
Lonza is a supplier to the pharmaceutical, biotech and specialty ingredients markets. The company also offers services and products ranging from active pharmaceutical ingredients to drinking water sanitizers, from nutritional and personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions tha... Read More